No Data
No Data
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $997
Pfizer Succeeds in Late-stage Trial for Colorectal Cancer Therapy
Novo Nordisk Stock Soars on New Weight-Loss Drug Results -- Barrons.com
Express News | Eli Lilly Shares Down 1.2% Premarket After Rival Novo Nordisk's Amycretin Obesity Drug Shows 22% Weight Loss in Early Trial
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Allurion (ALUR.US) stock price surged violently; its new weight loss therapy can maintain muscle mass.
On Thursday, Allurion's stock price soared 80% in after-hours trading, following reports that the company plans to conduct clinical research combining its gastric balloon weight loss product with GLP-1 drugs.